INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 155 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $2,821,000 | +80.6% | 202,239 | +78.8% | 0.04% | +105.9% |
Q2 2022 | $1,562,000 | +177.0% | 113,114 | +197.8% | 0.02% | +466.7% |
Q3 2021 | $564,000 | +37.2% | 37,988 | +84.7% | 0.00% | +50.0% |
Q2 2021 | $411,000 | -27.9% | 20,565 | -16.8% | 0.00% | -33.3% |
Q1 2021 | $570,000 | -27.0% | 24,703 | -21.9% | 0.00% | -25.0% |
Q4 2020 | $781,000 | -22.1% | 31,625 | +30.9% | 0.00% | -33.3% |
Q3 2020 | $1,002,000 | +164.4% | 24,156 | +205.0% | 0.01% | +100.0% |
Q2 2020 | $379,000 | -83.0% | 7,920 | -77.6% | 0.00% | -85.7% |
Q1 2020 | $2,225,000 | +309.0% | 35,347 | +705.2% | 0.02% | +320.0% |
Q4 2019 | $544,000 | +25.3% | 4,390 | -32.9% | 0.01% | +25.0% |
Q3 2019 | $434,000 | +70.2% | 6,545 | +104.1% | 0.00% | +100.0% |
Q2 2019 | $255,000 | -53.5% | 3,207 | -34.6% | 0.00% | -60.0% |
Q1 2019 | $548,000 | -73.3% | 4,903 | -75.9% | 0.01% | -72.2% |
Q4 2018 | $2,049,000 | -13.0% | 20,329 | +9.1% | 0.02% | +5.9% |
Q3 2018 | $2,354,000 | +830.4% | 18,629 | +517.3% | 0.02% | +750.0% |
Q2 2018 | $253,000 | -88.3% | 3,018 | -91.4% | 0.00% | -88.2% |
Q1 2018 | $2,159,000 | +29.5% | 35,087 | +23.0% | 0.02% | +6.2% |
Q4 2017 | $1,667,000 | +127.4% | 28,531 | +126.0% | 0.02% | +166.7% |
Q3 2017 | $733,000 | +211.9% | 12,627 | +551.5% | 0.01% | +200.0% |
Q2 2017 | $235,000 | +11.4% | 1,938 | -0.1% | 0.00% | 0.0% |
Q4 2016 | $211,000 | -66.7% | 1,940 | -49.6% | 0.00% | -71.4% |
Q3 2016 | $634,000 | -62.6% | 3,849 | -67.6% | 0.01% | -41.7% |
Q2 2016 | $1,697,000 | +77.3% | 11,894 | +59.6% | 0.01% | +71.4% |
Q1 2016 | $957,000 | +181.5% | 7,451 | +227.1% | 0.01% | +250.0% |
Q4 2015 | $340,000 | -90.0% | 2,278 | -88.9% | 0.00% | -90.0% |
Q3 2015 | $3,398,000 | +140.3% | 20,490 | +249.7% | 0.02% | +122.2% |
Q2 2015 | $1,414,000 | +23.2% | 5,859 | +43.9% | 0.01% | +28.6% |
Q1 2015 | $1,148,000 | +28.3% | 4,071 | -29.0% | 0.01% | +75.0% |
Q4 2014 | $895,000 | +88.8% | 5,737 | +186.7% | 0.00% | +33.3% |
Q3 2014 | $474,000 | -7.6% | 2,001 | -7.7% | 0.00% | 0.0% |
Q2 2014 | $513,000 | -24.0% | 2,168 | +6.0% | 0.00% | 0.0% |
Q1 2014 | $675,000 | +279.2% | 2,046 | -20.7% | 0.00% | +200.0% |
Q3 2013 | $178,000 | – | 2,579 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |